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Abstract
Background
Leukocyte telomere length (LTL) is a putative biological marker of immune system age, and
there are demonstrated associations between LTL and cardiovascular disease. This may be
due in part to the relationship of LTL with other biomarkers associated with cardiovascular
disease risk. However, the strength of associations between LTL and adiposity, metabolic,
proinflammatory, and cardiovascular biomarkers has not been systematically evaluated in a
United States nationally representative population.
Methods and Findings
We examined associations between LTL and 17 cardiovascular biomarkers, including lipo-
proteins, blood sugar, circulatory pressure, proinflammatory markers, kidney function, and
adiposity measures, in adults ages 20 to 84 from the cross-sectional US nationally represen-
tative 1999–2002 National Health and Nutrition Examination Survey (NHANES) (n = 7,252),
statistically adjusting for immune cell type distributions. We also examine whether these
associations differed systematically by age, race/ethnicity, gender, education, and income.
We found that a one unit difference in the following biomarkers were associated with
kilobase pair differences in LTL: BMI -0.00478 (95% CI -0.00749–-0.00206), waist circum-
ference -0.00211 (95% CI -0.00325–-0.000969), percentage of body fat -0.00516 (95% CI
-0.00761–-0.0027), high density lipoprotein (HDL) cholesterol 0.00179 (95% CI 0.000571–
0.00301), triglycerides -0.000285 (95% CI -0.000555–-0.0000158), pulse rate -0.00194
(95% CI -0.00317–-0.000705), C-reactive protein -0.0363 (95% CI 0.0601–-0.0124), cysta-
tin C -0.0391 (95% CI -0.0772–-0.00107). When using clinical cut-points we additionally
found associations between LTL and insulin resistance -0.0412 (95% CI -0.0685–-0.0139),
systolic blood pressure 0.0455 (95% CI 0.00137–0.0897), and diastolic blood pressure
-0.0674 (95% CI -0.126–-0.00889). These associations were 10%–15% greater without
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controlling for leukocyte cell types. There were very few differences in the associations by
age, race/ethnicity, gender, education, or income. Our findings are relevant to the relation-
ships between these cardiovascular biomarkers in the general population but not to cardio-
vascular disease as a clinical outcome.
Conclusions
LTL is most strongly associated with adiposity, but is also associated with biomarkers
across several physiological systems. LTL may thus be a predictor of cardiovascular dis-
ease through its association with multiple risk factors that are physiologically correlated with
risk for development of cardiovascular disease. Our results are consistent with LTL being a
biomarker of cardiovascular aging through established physiological mechanisms.
Author Summary
Why Was This Study Done?
• Leukocyte telomere length (LTL) is a biomarker of white blood cell division and is
strongly associated with age.
• There are still mixed findings on how LTL is related to different types of mortality.
• Observational evidence and quasi-experimental studies suggest that there is an asso-
ciation between shorter LTL and cardiovascular disease mortality.
• It is unclear, however, whether or not LTL is completely independent of already
known biological pathways of cardiovascular disease.
What Did the Researchers Do and Find?
• We examined US nationally representative data on participants ages 25 to 84 that
had LTL measured along with 17 other cardiovascular risk biomarkers.
• We found associations between LTL and measures of adiposity (BMI, waist circum-
ference, percentage of body fat), along with C-reactive protein, cystatin C, high-den-
sity lipoprotein (HDL) cholesterol, triglycerides, insulin resistance, systolic blood
pressure, diastolic blood pressure, and pulse rate.
• We did not find that there were a meaningful number of differences in these relation-
ships by age, race/ethnicity, or socioeconomic position, suggesting that the associa-
tions we find are generally consistent across different population groups.
What Do These Findings Mean?
• Our findings suggest that LTL is associated with cardiovascular risk factors across
different physiological systems.
• The study findings do not have any implications for whether LTL is a cause of cardio-
vascular disease.
Leukocyte Telomere Length and Biomarkers of Cardiovascular Disease Risk
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Introduction
Shorter leukocyte telomere length (LTL) is significantly associated with increased risk of car-
diovascular disease, irrespective of adjustment for conventional risk factors [1]. A meta-analy-
sis of 24 studies with 43,725 participants and 8,400 patients with cardiovascular disease
estimated a relative risk of 1.54 (95% CI 1.30–1.83), comparing those with the longest to short-
est third of LTL [1]. Although these finding are consistent with a role for LTL in cardiovascular
disease etiology, the critical details of how LTL is related to known metabolic pro-inflamma-
tory markers and cardiovascular risk factors in the pathway to cardiovascular disease are
unclear [2]. It is thought that telomere length shortens in relationship to multiple types of bio-
chemical stressors and thus may represent a cumulative index of known risk factors. Our
study will contribute to answering this question using a large US nationally representative
sample with a comprehensive number of biomarkers measured along with LTL. Examining
the relationship of telomere length with multiple biomarkers concurrently will inform us of
whether LTL might be a marker for one primary risk factor, such as inflammation, or of multi-
ple risk factors. This analysis will thus help to better understand whether LTL represents a
unique biomarker that is independent from other known risk factors for cardiovascular
disease.
In previous research, LTL was associated with myocardial infarction and stroke among
younger (73 years) individuals [3]; rate of LTL shortening was associated with cardiovascular
disease among elderly men [4]; LTL was associated with congestive heart failure [5]; and LTL
was associated with prospective cardiovascular disease events [6]. Single nucleotide polymor-
phisms (SNPs) that are associated with telomere length are also associated with cardiovascular
disease, offering a complementary source of evidence consistent with the observational data
[7]. There are several prior studies that have each examined cardiovascular risk biomarkers
and their association with LTL. The most comprehensive analysis to date examined approxi-
mately 2,500 community-dwelling white individuals from Belgium aged 35–55 who did not
have diagnosed cardiovascular disease [8]. They found very little correlation with traditional
lipid biomarkers but did find associations with markers of inflammation, including C-reactive
protein. Other studies have found mixed associations between diastolic blood pressure and
LTL, with one study finding an inverse association [3] and another no association [4]. A prior
study of a nationally representative sample of 1,000 individuals in Costa Rica found a statisti-
cally significant positive association with systolic blood pressure [9].
To our knowledge, this is the first study to comprehensively examine the relationships
between cardiovascular risk factor biomarkers and LTL in a large, US nationally representative
sample, allowing us to either confirm or refute the results of recent studies on telomere length
in relation to specific metabolic, immune function, and cardiovascular biomarkers from
smaller, isolated populations and to perform analyses controlling for multiple measures of
socioeconomic position, clinical variables, and chronic disease as potentially confounding var-
iables. In addition, because we have a nationally representative study that oversampled racial/
ethnic minority populations, we can also appropriately test for effect measure modification by
age, race/ethnicity, gender, education, and income. This is critical, as a prior meta-analysis
suggested that there may be substantial heterogeneity across demographic groups in the rela-
tionship between LTL and myocardial infarction but this study did not have enough data to
robustly test this hypothesis [10]. A further contribution of our work is examining these associ-
ations among individuals of all ages, because an important potential contribution of LTL is
using it as a biomarker of aging across the life course. Prior studies have focused primarily on
relationships with cardiovascular biomarkers in the population aged 65 and older [11]. In
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addition, the use of a wide range of ages is important because it allows for analyses conditional
on current chronic disease, which is much more common among older individuals.
Because LTL comes from a mix of blood types that have systematically different extents of
differentiation depending on function and thus have different mean telomere lengths, previ-
ously demonstrated associations of LTL and health outcomes may be confounded by cell type
composition [12]. We thus also examine associations statistically controlling for cell type com-
position. Finally, given the possibility that a linear model may not be the appropriate func-
tional form for examining the association between LTL and continuous cardiovascular
biomarkers, we present sensitivity analyses fit with penalized spline models and also examine
associations with clinical cut-points of biomarkers.
Materials and Methods
Study Population
We pooled data from the 1999–2000 and 2001–2002 cycles of National Health and Nutrition
Examination Survey (NHANES), a nationally representative survey and physical examination
of the civilian, noninstitutionalized US population conducted by the US Centers for Disease
Control and Prevention (CDC). All data that we used for the analyses presented here are avail-
able for public download (http://www.cdc.gov/nchs/nhanes/nhanes_questionnaires.htm).
Between 1999 and 2002, DNA samples were stored from NHANES participants aged 20 and
older to establish a national probability sample of genetic material for future research. Our
analysis is limited to these years of data because of the availability of DNA for LTL assay during
only these years. We excluded individuals aged 85 and older from our analysis because of mor-
tality selection over this age and because most traditional risk factors for disease are not predic-
tive of morbidity and mortality in this population. Of the 9,191 participants aged 20–84 in the
sample who were eligible to provide DNA, 7,525 (82%) provided DNA, consented to its use in
future research, and had a sufficient quality and quantity of DNA to estimate telomere length.
Non-Hispanic blacks, women, and subjects older than 60 years of age were less likely to give
consent for future genetic research [13]. Participants provided written consent for participa-
tion in this study, and all study protocols were approved by the Institutional Review Board at
the CDC.
LTL Measurements
Aliquots of purified DNA were provided by the National Center for Health Statistics. DNA
was isolated from whole blood using the Puregene (D-50K) kit protocol (Gentra Systems, Inc.,
Minneapolis, Minnesota) and stored at -80˚C. To measure mean LTL, quantitative PCR assay
was used to determine the relative ratio of telomere repeat copy number to single-copy gene
copy number (T/S ratio), with the full details of this standard protocol described elsewhere
[14,15]. Each sample was assayed three times on three different days. The samples were assayed
on duplicate wells, resulting in six measurements per sample. Sample plates were assayed in
groups of three plates, and no two plates were grouped together more than once. Each assay
plate contained 96 control wells. Any assay runs with eight or more invalid control wells were
considered a failed run and were excluded from further analysis (<1% of runs). The mean of
the T/S ratio values was calculated, and the largest and the smallest T/S ratio values in the set
were marked as potential outliers. Then the mean of the T/S ratio value was calculated without
the potential outliers. If the absolute value of the log of the ratio between the recalculated mean
(excluding the potential outliers) to the value of the potential outlier was greater than 0.4, then
the value was marked as an outlier (98.7% of all samples contained no outliers). The LTL assay
lab was blind to the sample characteristics. The inter-assay coefficient of variability for LTL
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was 4%. The equation for conversion from T/S ratio to kb pairs used was 3,274 + 2,413  (T/S) /
1,000 [16]. This conversion ratio is likely to differ between laboratories and even between assays
within the same lab; thus, exact kb pair values we report should be used as an approximation of
actual telomere length. Although this does not impact the internal validity of the analyses pre-
sented here, the absolute level of base pair length should not be used in direct comparison to
other studies. The assays were conducted in the Blackburn Laboratory at the University of Cali-
fornia, San Francisco. Due to the extreme right skew (high values) of a small number of observa-
tions that are likely to be assay errors and not biologically plausible, we excluded the top 1% of
measures (n = 76) from all of our analyses.
Blood Sample Characteristics
NHANES 1999–2002 measured a number of characteristics of the blood samples from which
DNA was extracted. These characteristics included the following: white blood cells (SI), lym-
phocytes (%), monocytes (%), neutrophils (%), eosinophils (%), and basophils (%). Overall
white blood cell count may act as a confounder because it can capture whether infection is
occurring, which may have resulted in proliferation of additional new cells within each cell
type, which may have different telomere lengths, and which may not be captured by the five
cell type composition measures. Fig 1 shows the correlation structure between these six factors.
The only strong correlation is between neutrophils and lymphocytes. This suggests that most
of these measures are capturing unique information about the blood component cell type
composition.
Biomarker Outcomes Examined
NHANES 1999–2002 allows for an examination of 17 factors within six categories of biomark-
ers that are risk factors for cardiovascular disease: lipoproteins (high-density lipoprotein
[HDL] cholesterol, low density lipoprotein [LDL] cholesterol, triglycerides), blood sugar (glu-
cose, hemoglobin A1c, insulin resistance), circulatory pressure (systolic blood pressure, dia-
stolic blood pressure, pulse rate), proinflammatory (C-reactive protein, fibrinogen), kidney
function (cystatin C, glomerular filtration rate, urine albumin to creatinine ratio [ACR]), and
adiposity measures (body mass index [BMI], waist circumference, estimated percentage of
body fat). The details of the measurement of these factors have been described in the NHANES
documentation [17]. We used values of serum creatinine to estimate the glomerular filtration
rate using the reexpressed four-variable MDRD Study equation (glomerular filtration
rate = 175 × standardized (Scr)−1.154 × (age)−0.203) [18] without equivalization for race/ethnicity
and gender (we statistically controlled for race/ethnicity and gender in our analyses). The glo-
merular filtration rate is presented as mL/min/1.73 m2. Insulin resistance was measured by
HOMA-IR, which was calculated as the product of fasting glucose (mmol/L) and fasting insu-
lin (μU/ML) divided by 22.5. Urine albumin creatinine ratio was calculated as urine albumin
divided by urinary creatinine and reported as mg/g. Unless otherwise indicated, biomarkers
are reported in SI units. Fig 2 shows the correlation structure of these 17 measures, ordered by
a hierarchical clustering algorithm. Although we see an expected level of correlation between
measures of adiposity, including BMI and waist circumference as well as hemoglobin A1c and
glucose, most other measures are not substantially correlated (>0.6). This suggests that it is
appropriate to examine this wide range of biomarkers that capture generally unique aspects of
physiology within several different systems. Because the health risks of levels of each of these
biomarkers may in some cases be nonlinear, we also examined each as a clinical threshold for
a high-risk level of the biomarker. We used the following levels as indicating an increased level
of clinical risk based on ATP III guidelines and other relevant literature: HDL cholesterol
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(<40 mg/dl) [19], LDL cholesterol (160 mg/dl) [19], triglycerides (200 mg/dl) [19], glucose
(>100 mg/dl) [20], hemoglobin A1c (>5.4%) [21], HOMA-IR (2.5) [22], systolic blood pres-
sure (140 mm Hg) [23], diastolic blood pressure (90 mm Hg) [23], pulse rate (83 beats
per minute) [24,25], C-reactive protein (>3.0 mg/L) [26], fibrinogen (>4.0 g/mL) [27], cysta-
tin C (>1.29 mg/L) [28], estimated glomerular filtration rate (<60 mL/min/1.73 m2) [29],
urine ACR (>30 mg/g) [30], BMI (30 kg/m2) [31], waist circumference (>102 cm for men,
>88 cm for women) [31], and estimated percentage of body fat (>25% for men,>30% for
women) [32]. We also examine a summary measure of cardiometabolic risk—the metabolic
syndrome, which is a sum of whether a participant is above the clinical cut-point for waist cir-
cumference, triglycerides, HDL cholesterol, systolic blood pressure, and glucose. Individuals
with a score of 3 or more are considered to have the metabolic syndrome [33].
Demographic Variables
All demographic variables that we use in our analysis are derived from respondent self-report,
including race/ethnicity (white, black, Mexican American, and other), marital status (married
Fig 1. Correlation structure of blood constituent cell types, ages 20–84, NHANES 1999–2002. The scale to
the right of the figure indicates the strength of correlation, with darker and larger dots indicating stronger correlation.
The six constituent blood components are ordered by hierarchical clustering.
doi:10.1371/journal.pmed.1002188.g001
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or living with partner versus not), place of birth (outside of the US or within the US), level of
educational attainment (less than high school, high school, more than high school), and occu-
pation (white collar and professional; white collar, semi-routine; blue collar, high skill; blue
collar, semi-routine; not working). The occupation measure was based on the self-reported
type of work that was done the longest, using a previously described classification [34]. Our
measure of income was the NHANES calculated poverty–income ratio (PIR), or the ratio of
household income to poverty threshold adjusted for family size and inflation and used as a
continuous measure.
Health and Health Behaviors
All health and health behavior measures were derived from self-reported data. Respondents
were asked separate questions on whether they had “ever been told by a doctor or other health
professional that” they had high blood pressure or hypertension, had diabetes, or had conges-
tive heart failure, coronary heart disease, angina, angina pectoris, a heart attack, or a stroke.
Fig 2. Correlation structure of biomarkers, ages 20–84, NHANES 1999–2002. The scale to the right of the
figure indicates the strength of correlation, with darker and larger dots indicating stronger correlation. The 17
biomarker components are ordered by hierarchical clustering.
doi:10.1371/journal.pmed.1002188.g002
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Participants were also asked if they had ever been told of having “weak or failing kidneys? Do
not include kidney stones, bladder infections, or incontinence.” Participants were asked
whether they had smoked at least 100 cigarettes in their entire life and whether they currently
smoke cigarettes, which we label as ever smoked and current smoker. Participants were also
asked whether they had participated in “moderate activities that cause only light sweating or a
slight to moderate increase in breathing or heart rate. Some examples are brisk walking,
bicycling for pleasure, golf and dancing” over the past 30 days, as well as whether they had par-
ticipated in “vigorous activities for at least ten minutes that cause heavy sweating or large
increases in breathing or heart rate? Some examples are running, lap swimming, aerobics clas-
ses, or fast bicycling” at least once over the last 30 days.
Missing Data
Of the 7,525 individuals in the analytic sample, there were the following numbers of individu-
als missing demographic, health behavior, and chronic disease variables: education (1), income
(660), occupation (3,072), marital status (358), current smoker (14), vigorous physical activity
(6), hypertension (75), and diabetes (3). We also imputed missing data for cardiovascular bio-
markers that were missing the following number of observations: HDL cholesterol (6), LDL
cholesterol (4,217), triglycerides (4,084), glucose (4,086), insulin (3,831), hemoglobin A1c (5),
systolic blood pressure (241), diastolic blood pressure (241), pulse pressure (206), C-reactive
protein (1), fibrinogen (2,783), cystatin C (3,711), glomerular filtration rate (4,086), urine albu-
min to creatinine ratio (100), BMI (197), waist circumference (224), and percentage of body
fat (4,672). Note that samples were intentionally smaller for LDL cholesterol, triglycerides, glu-
cose, and insulin because we examine these only in the subsample that fasted overnight, and
special survey sample weights for this subsample are used. The estimated body fat from bioim-
pedance spectroscopy has a larger number of missing observations because this was only per-
formed on participants up to the age of 49 years old. Cystatin C was measured only on
participants aged 60 and above and on a 25% random sample of participants aged 12–59 years
old. Fibrinogen was assayed only on individuals aged 40 and older. In order to avoid the bias
caused by complete case analysis, we imputed missing variables for the demographic control
variables and cardiovascular disease biomarkers using a nonparametric missing value imputa-
tion with Random Forest, implemented with the R package missForest [35] fit with 100 trees.
This approach has several advantages for our particular study as compared to multiple imputa-
tion methods for missing data, including that it can be used with specialized survey functions
and nonlinear models. This method of imputing missing data has been shown to compare
favorably, with the missForest algorithm having the smallest prediction difference between the
imputed and non-missing data sets [36]. The large number of missing observations for occu-
pation mean that there will be some residual confounding to measurement error in the
imputed data for occupation, but this approach is preferable to the larger degree of uncon-
trolled confounding that would exist if excluding occupation from the models [37]. Note that
based on prior empirical work in the literature we did not impute missing values of our depen-
dent variable, LTL, as this generally results in either no improvement in model accuracy or
more biased results [38,39].
Statistical Analysis
Analyses were conducted in R using the survey package [40], with models fit using the
svyglm() function that uses inverse probability weighting and design-based standard errors
All analyses accounted for the clustered sampling design and the examination survey weights
as required for appropriate analysis of this data [41]. For variables that were only measured for
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individuals who participated in an overnight fast (LDL cholesterol, triglycerides, glucose, insu-
lin), fasting examination survey weights were used.
We used multivariable regression models to assess the relationship between LTL and each
biomarker. Consistent with most prior literature on biomarkers and telomere length, we
examined telomere length as a linear variable.
For all analyses, we present a model 1 that shows the coefficient from a simple linear regres-
sion model for the cell sample characteristic or cardiovascular biomarker in relation to the
dependent variable of LTL. In model 2, we fit a multiple linear regression model that included
additional variables that were demonstrated by Needham et al. (2013) to be predictors of LTL
in this study population: race/ethnicity (indicators for white, Mexican American, black, and
other), education (indicators for less than high school and high school diploma, with some col-
lege or more as the omitted comparison category), income, occupation (white collar and pro-
fessional; white collar, semi-routine; blue collar, high skill; blue collar, semi-routine; not
working), married, foreign born, age (as continuous linear), and age-squared. The use of con-
tinuous linear age along with an age-squared term is important for analyses of LTL given the
strength with which it is associated with age and the potential for nonlinearity in this associa-
tion [42]. Model 3 additionally includes two measures of smoking and two measures of physi-
cal activity, as these may act as confounding factors of the relationship between LTL and
cardiovascular biomarkers. We fit this as a separate model because we want to assess whether
the associations observed between biomarkers and LTL are attenuated due to health-related
behaviors that are associated with LTL. Model 4 additionally includes the six available cell type
composition measures. We fit each of the above models both with continuous levels of the bio-
markers and with the two category clinical risk threshold measures. We also performed sensi-
tivity analysis, restricting the population to individuals that did not have chronic disease risk,
in order to test whether our results for the general population also apply to a health population.
In particular, these robustness checks of results allow us to address the possible limitation that
the presence of chronic disease may cause associations between LTL and cardiovascular dis-
ease risk biomarkers.
We a priori specified that we would test for effect measure modification between the con-
tinuous measures of the biomarkers and LTL by gender, age (20–44 and 65–84), income (PIR),
education (less than high school), and race/ethnicity (black and Mexican American) and
report the magnitude of differences observed and the 95% CIs when interaction terms did not
include the null of no association.
Finally, given that there are unclear priors on the best functional form to model the rela-
tionship between each of these biomarkers and LTL, we conducted sensitivity analysis using a
penalized spline model that allows there to be a nonlinear relationship between dependent and
independent variables. These models were fit using a generalized additive mixed model that
fits a number of splines across the data then uses a penalized fitting algorithm to fit a number
of slopes that best fit the data. We specified a maximum of four degrees of freedom for the
spline basis, with the best fitting model fit by generalized cross validation [43].
Results
Sample Characteristics
Table 1 shows the weighted distribution of population demographic characteristics for the full
NHANES 1999–2002 population aged 20–84, the population with measured telomere length,
as well as the characteristics for the population with measured telomere length for which miss-
ing values were imputed. For the full NHANES population, the distribution of these factors
reflects their distribution in the US noninstitutionalized population consistent with the
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sampling design of the NHANES study. The population with measured telomere length differs
primarily because of who consented to the future use of their DNA. Although the populations
are very similar, there are about 1% fewer black participants in the sample with telomere
length, as well as fewer foreign-born individuals. The distributions by education, income, and
occupation are similar. The sample distributions for the final imputed sample only differ nota-
bly for occupational classification due to the large number of missing responses for this ques-
tion. Fig 3 shows the distribution of LTL.
LTL and Constituent Cell Types
Table 2 shows coefficients of association between cell types comprising the blood sample from
which DNA was extracted and the LTL assayed from the leukocytes. The model-based coeffi-
cients in the table can be interpreted as the difference in 1 kb pair of LTL associated with a one
unit change in the cell type. For example, the coefficient of 0.0272 for Basophils in model 1
means that a difference in 1 kb of telomere length is associated with 2.72% difference in Baso-
phils. Model 1 presents the unadjusted correlation coefficients. Model 2 includes social and
demographic factors. Model 3 additionally controls health behaviors. In the unadjusted model
Table 1. Sample characteristics, ages 20–84, NHANES 1999–2002.
Full NHANES (n = 9,191) With Telomere Length (n = 7,252) Final Imputed (n = 7,252)
Proportion/mean Proportion/mean Proportion/mean
Age (mean) 45.5 45.7 45.7
Female 0.52 0.511 0.511
Race/ethnicity
Black 0.108 0.093 0.093
White 0.707 0.727 0.727
Mexican American 0.071 0.071 0.071
Other race/ethnicity 0.113 0.109 0.109
Education
Less than high school 0.216 0.212 0.212
High school 0.256 0.26 0.26
Some college 0.526 0.527 0.527
Poverty: Income ratio (mean) 2.98 3.02 3.00
Occupation
White collar—high 0.241 0.247 0.412
Blue Collar—high 0.112 0.115 0.115
White collar—low 0.223 0.222 0.175
Blue collar—low 0.392 0.384 0.263
No work 0.033 0.032 0.029
Foreign born 0.154 0.147 0.148
Married 0.664 0.660 0.664
Smoked (ever) 0.497 0.503 0.503
Smoker (current) 0.247 0.248 0.248
Physical activity (moderate) 0.472 0.484 0.484
Physical activity (vigorous) 0.351 0.358 0.358
Kidney disease 0.021 0.021 0.021
Hypertension 0.254 0.255 0.255
Diabetes 0.066 0.066 0.066
Cardiovascular disease 0.08 0.08 0.08
doi:10.1371/journal.pmed.1002188.t001
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Fig 3. Distribution of LTL (kb pairs) in the sample, ages 20–84, NHANES 1999–2002.
doi:10.1371/journal.pmed.1002188.g003
Table 2. Association of LTL with concentration of white blood cells and constituent cell types, ages 20 to 84, NHANES 1999–2002.
Model 1—unadjusted Model 2—demographic adjusted Model 3—demographic + health-
related behaviors
coef 95% CI coef 95% CI coef 95% CI
White blood cells (SI) -0.00984 -0.0219, 0.00224 -0.0161** -0.0264, -0.00576 -0.0152* -0.0253, -0.0051
Lymphocytes (%) 0.00288* 0.0000759, 0.00568 0.0000529 -0.00229, 0.0024 -0.000106 -0.00241, 0.0022
Monocytes (%) -0.0126* -0.0217, -0.00358 -0.00136 -0.00985, 0.00713 -0.00197 -0.0105, 0.0066
Neutrophils (%) -0.00109 -0.00355, 0.00136 0.000169 -0.0019, 0.00224 0.000354 -0.00168, 0.00239
Eosinophils (%) -0.00989** -0.016, -0.00376 -0.00433 -0.0103, 0.00167 -0.00468 -0.0107, 0.0013
Basophils (%) 0.0272 -0.0264, 0.0807 0.0519 -0.000992, 0.105 0.0493 -0.00445, 0.103
Sample size for all analyses is n = 7,252. The dependent variable in all models is LTL (in kbp). Each line shows coefficients and 95% CIs from separate
statistical models. Model 1 does not adjust for any covariables. Model 2 adjusts for the following covariables: race/ethnicity (white, Mexican American,
black, and other), gender, foreign birthplace, education (less than high school, high school diploma, more than high school), class of work (white collar high,
blue collar high, white collar low, blue collar low, no work), income, marital status (married or living with partner), age (as continuous), and age-squared.
Model 3 additionally controls for ever smoked, current smoker, moderate physical activity, and vigorous physical activity.
*p < 0.05
**p < 0.01
doi:10.1371/journal.pmed.1002188.t002
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1, monocytes and eosinophils were negatively associated with LTL, and lymphocytes were pos-
itively associated, with 95% CIs that did not include 0. After controlling for demographic fac-
tors, the concentration of white blood cells is significantly associated with LTL. The results
from model 3 are similar, for which a higher level of white blood cells is associated with lower
LTL. We also examined this model in a restricted population of individuals aged 25 to 84 who
did not have kidney disease, hypertension, diabetes, or cardiovascular disease, and associations
were either similarly close to 0 or the magnitude of the association did not differ by more than
10% (S1 Table).
We also examined interactions with gender, race/ethnicity (black and Mexican American),
education (less than high school diploma), income (continuous), and age (25–44 and 65–84)—
a total of 42 interactions (S2 Table). We find a more negative association for monocytes for
black participants (interaction coefficient = -0.0202; 95% CI -0.0336–-0.00684), a more posi-
tive association of eosinophils with higher income (interaction coefficient = 0.00469; 95% CI
0.00149–0.00789), and both lower lymphocytes (interaction coefficient = -0.00348; 95% CI
-0.00657–-0.000391) and higher neutrophils (interaction coefficient = 0.00290; 95% CI
0.000418–0.00539) among participants age 65 and older. We thus found four interactions for
which the null of 0 was not included in the confidence interval when 2–3 would be expected
by chance alone.
LTL and Biomarkers
Table 3 presents coefficients of the association between biomarkers and LTL in the categories
of lipoproteins, blood sugar, circulatory pressure, proinflammatory, kidney function, and adi-
posity measures. There were associations with LTL for 13 of the 17 biomarkers examined in
the unadjusted models (model 1) for which the null association of 0 was not within the esti-
mated 95% CIs, with eight of these associations remaining after controlling for demographic
factors, health behaviors, and cell type (model 4). These factors were HDL cholesterol, triglyc-
erides, pulse rate, C-reactive protein, cystatin C, BMI, waist circumference, and percentage of
body fat. There was no association with the summary measure of metabolic syndrome after
controlling for demographic characteristics, nor when additionally controlling for health-
related behaviors. There was generally between a 10%–15% reduction in the magnitude of the
coefficient after controlling for cell type (comparing models 2 and 3 to model 4), consistent
with the fact that there may be some confounding of the associations we observed in models 2
and 3 by cell type. Fig 4 shows a dot plot of coefficients and 95% CIs comparing the magni-
tudes of association with LTL across each of the 17 biomarkers and the summary measure of
the metabolic syndrome. The coefficients are from the same model as model 4, but the bio-
markers are standardized (by dividing by their standard deviation), so the magnitude of the
associations with LTL can be directly compared to each other. The scale of interpretation is
how much of a standard deviation of the biomarker is associated with a 1 kb pair difference in
LTL. The strongest negative correlations were for percentage of body fat, BMI, C-reactive pro-
tein, and waist circumference, followed by pulse. The strongest positive correlation was for
HDL, which was of a similar magnitude of association as pulse rate. Note that HDL is the only
biomarker we examined where higher levels are associated with lower cardiovascular disease
risk [44].
We also examined the full model 4 in a restricted population of individuals aged 25 to 84
who did not have kidney disease, hypertension, diabetes, or cardiovascular disease (S3 Table).
Coefficients of association were similar between the full population and the restricted population
with the exception of cystatin C, for which coefficient estimates did not have overlapping 95%
CIs. In the full population the association with LTL was -0.0391 (95% CI -0.0772–-0.00701),
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whereas in the restricted healthy population the association with LTL was stronger, -0.24 (95%
CI -0.39–-0.904).
We note that only a small number of interactions were observed based on our a priori spec-
ification to test for heterogeneity of association based on seven characteristics: female, black,
Mexican American, less than a high school education, poverty income ratio, and ages 20 to 44
and ages 65 to 84. Based on these seven factors with 17 cardiovascular biomarkers, we tested
119 interactions (S4 Table). We note interactions for which the null of 0 for the interaction
coefficient was not included in the estimated 95% CI. For triglycerides, there was a stronger
association for women (interaction coefficient 0.000485; 95% CI 0.0000731–0.000897); for
LDL cholesterol, there was a stronger relationship among black participants (interaction coef-
ficient = 0.0020; 95% CI 0.000287–0.00376); for glomerular filtration rate, there was a stronger
relationship among black participants (interaction coefficient = 0.000951, 95% CI 0.0000755–
Fig 4. Regression coefficients for relationship between biomarkers and LTL, in standard deviations of biomarker per kb of LTL, ages 20–84,
NHANES 1999–2002.
doi:10.1371/journal.pmed.1002188.g004
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0.00183); for percentage of body fat, there was a stronger relationship among black participants
(interaction coefficient = 0.00697, 95% CI 0.00311–0.0108); for triglycerides, there was a stron-
ger relationship among Mexican Americans (interaction coefficient = 0.00624, 95% CI
0.0000165–0.00123); for HbA1c, there was a stronger relationship among those with less than
a high school diploma (interaction coefficient = 0.042, 95% CI 0.0158–0.0683); for percentage
of body fat, there was a weaker relationship among those with lower levels of income (interac-
tion coefficient = -0.00148, 95% CI -0.00232–-0.000643); for diastolic blood pressure, there
was a weaker relationship among participants aged 25–44 (interaction coefficient = -0.00288,
95% CI -0.0051–-0.000652); and for glomerular filtration rate, there was a stronger relation-
ship among participants aged 65 and above (interaction coefficient = 0.00107, 95% CI
0.0000132–0.00212). We found a total of nine interactions for which CIs did not include the
null of no association, but, as we tested 119 interactions, we would expect six by chance alone.
We therefore do not find substantial evidence for there being any systematic differences in
associations in different groups of the population, but there is some evidence that there may be
stronger associations between LTL and cardiovascular risk biomarkers among black
participants.
We also repeated the primary analyses using dichotomous risk indicators of biomarkers,
and results were generally similar (Table 4). Most of the associations with continuous mea-
sures were replicated in terms of magnitude, even though coefficients differed. Although asso-
ciations with clinical thresholds of lipids were notably weaker than with the continuous
measures, CIs for estimates were generally overlapping. The primary difference was that there
was a stronger association with diastolic blood pressure and insulin resistance when using the
clinical cut-point that was not observed for the continuous measure.
Table 5 considers a model that includes all of the biomarkers in the same multivariable
model so as to examine whether predictors remain associated independently of other cardio-
vascular disease biomarkers. Although interpretation of the coefficients should be done with
caution because they are conditional on other biomarkers and the causal ordering of these bio-
markers is not well characterized, this model provides an additional perspective on which car-
diovascular biomarkers are the strongest relative predictors of LTL. In the model that includes
no demographic controls, triglycerides, systolic blood pressure, diastolic blood pressure,
cystatin C, glomerular filtration rate, BMI, waist circumference, and body fat percentage are
associated with LTL. After controlling for demographic factors, only the coefficient for the
association of pulse rate and LTL has estimated 95% CIs that do not include the null of no
association. However, these results should be interpreted in conjunction with the other find-
ings, as domains that have more correlated measures, for example measures of adiposity, will
be more attenuated by controlling for all of these measures in a single model.
Finally, we also examine the potential for nonlinear relationships between levels of cardio-
vascular biomarkers and LTL (Fig 5). In general, relationships do not deviate strongly from
linearity, albeit with a few exceptions. With glucose, HbA1c, glomerular filtration rate, and sys-
tolic blood pressure, there is a weakening of the association above 6.5 kb pairs. Thus, even
though there is a nonlinear relationship, there tends to be a linear association across the bulk
of the data (between 5 and 6.5 kb pairs as shown in Fig 3), with nonlinearity existing primarily
above 6.5 kb pairs. The exception to this is for diastolic blood pressure, for which there is an
inverted U-shaped relationship.
Discussion
The purpose of our study was to examine whether LTL is independent of other known biologi-
cal risk markers of cardiovascular disease. This is an important question given associations of
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LTL with cardiovascular disease mortality. The significance of this question is whether across
the life course LTL is independent of already well-documented biological mechanisms of car-
diovascular disease risk. Our findings suggest that, among a nationally representative US pop-
ulation, there are moderate correlations between LTL and important cardiovascular risk
factors, even after accounting for age, social and demographic factors, health behaviors, and
white blood cell types. We found that controlling for cell type reduced magnitudes of associa-
tion by between 10% and 20%.
Table 4. Regression of LTL on clinical cut-points of biomarkers, ages 20–84, NHANES 1999–2002.
Model 1—unadjusted Model 2—demographic
adjusted
Model 3—demographic
+ clinical adjusted
Model 4—demographic
+ clinical + cell type adjusted
coef 95% CI coef 95% CI coef 95% CI coef 95% CI
Lipoproteins
HDL cholesterol -0.035 -0.0772, 0.00711 -0.043* -0.0784, -0.0076 -0.0388* -0.0736, -0.00393 -0.0311 -0.0655, 0.00339
LDL cholesterol 0.0131 -0.0641, 0.0903 0.0638 -0.0087, 0.136 0.0594 -0.014, 0.133 0.0581 -0.0156, 0.132
Triglycerides -0.138*** -0.199, -0.0762 -0.062* -0.118, -0.00628 -0.0576* -0.111, -0.00422 -0.0504 -0.102, 0.00152
Blood sugar
Glucose -0.171*** -0.222, -0.12 0.012 -0.0339, 0.058 0.0154 -0.0291, 0.0598 0.0228 -0.02, 0.0655
Insulin resistance -0.138*** -0.166, -0.111 -0.055*** -0.0807, -0.0292 -0.0527** -0.0783, -0.0271 -0.0412* -0.0685, -0.0139
HbA1c -0.175*** -0.212, -0.138 -0.012 -0.0581, 0.0342 -0.00734 -0.0546, 0.04 0.00645 -0.0423, 0.0552
Circulatory pressure
Systolic blood
pressure
-0.22*** -0.27, -0.17 0.0442* 0.00103, 0.0873 0.0449* 0.00149, 0.0884 0.0455* 0.00137, 0.0897
Diastolic blood
pressure
-0.0872** -0.141, -0.0331 -0.067* -0.125, -0.00918 -0.066* -0.123, -0.00858 -0.0674* -0.126, -0.00889
Pulse rate 0.0123 -0.0249, 0.0495 -0.0307 -0.0641, 0.0028 -0.0258 -0.058, 0.00649 -0.0161 -0.0482, 0.0161
Immune function
C-reactive protein -0.189* -0.363, -0.015 -0.13 -0.264, 0.00361 -0.119 -0.254, 0.0155 -0.0931 -0.225, 0.0391
Fibrinogin -0.185*** -0.235, -0.135 -0.0257 -0.0811, 0.0297 -0.0225 -0.0762, 0.0312 -0.00777 -0.0575, 0.0419
Kidney function
Cystatin C -0.352*** -0.421, -0.283 -0.0345 -0.0989, 0.0298 -0.0334 -0.0965, 0.0297 -0.0279 -0.0909, 0.0351
Glomerular
filtration rate
-0.386*** -0.506, -0.267 -0.0744 -0.167, 0.0177 -0.0695 -0.16, 0.021 -0.0608 -0.155, 0.033
Albumin:
Creatinine
-0.158*** -0.223, -0.0924 -0.0312 -0.0912, 0.0289 -0.0285 -0.0884, 0.0313 -0.0235 -0.0819, 0.0349
Adiposity
BMI -0.0838*** -0.118, -0.0498 -0.0617** -0.0936, -0.0298 -0.0616** -0.0937, -0.0294 -0.0526* -0.0827, -0.0225
waist
circumference
-0.129*** -0.167, -0.0921 -0.0635** -0.0987, -0.0283 -0.0617** -0.0962, -0.0271 -0.0509* -0.0843, -0.0175
% body fat -0.188*** -0.231, -0.145 -0.0489* -0.0975, -0.000342 -0.0437 -0.0921, 0.00468 -0.0357 -0.0848, 0.0134
Metabolic
syndrome
-0.0734*** -0.0931, -0.0538 -0.0153 -0.0317, 0.0011 -0.013 -0.0284, 0.00238 -0.00985 -0.0244, 0.00469
The sample size for components that used the fasting weights was 3,407 (LDL cholesterol, triglycerides, glucose, and insulin resistance); sample size for all
other measures was 7,252. Model 4 adjusts for the following covariables: race/ethnicity (white, Mexican American, black, and other), gender, foreign
birthplace, education (less than high school, high school diploma, more than high school), class of work (white collar high, blue collar high, white collar low,
blue collar low, no work), income, marital status (married or living with partner), age (as continuous), age-squared, white blood cells (SI), lymphocytes (%),
monocytes (%), basophils (%), eosinophils (%), neutrophils (%), ever smoked, current smoker, moderate physical activity, and vigorous physical activity.
*p < 0.05
**p < 0.01
***p < 0.001.
doi:10.1371/journal.pmed.1002188.t004
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We found association with LTL for two measure of lipoprotein (HDL cholesterol, triglycer-
ides), one measure of blood sugar (insulin resistance), three measures of circulatory pressure
(systolic blood pressure, diastolic blood pressure, and pulse rate), one proinflammatory
marker (C-reactive protein), one measure of kidney function (cystatin C), and all three mea-
sures of adiposity (BMI, waist circumference, percentage of body fat). Among adiposity mea-
sures, percentage of body fat had the strongest association in independent models. LTL was
not associated with a measure of overall cardiovascular risk—the metabolic syndrome—
because of its unique association with particular cardiovascular biomarkers. This study also
allowed us to examine whether these relationships differed by age, gender, race/ethnicity, edu-
cation, and income. This question is important because relationships between LTL and mor-
tality have been found to differ by some of these domains [45]. In examining interactions
between LTL and the 17 biomarkers, we found only slightly more interactions than would be
expected by chance alone, suggesting that the relationships we present are fairly consistent
across demographic groups.
Table 5. Multivariable regression of LTL on all biomarkers, age 20–84, NHANES 1999–2002.
Model 1—unadjusted Model 2—demographic adjusted
coef 95% CI coef 95% CI
Lipoproteins
HDL cholesterol -0.0284 -0.0676, 0.0108 0.0158 -0.0224, 0.054
LDL cholesterol -0.00285 -0.024, 0.0183 0.00938 -0.00903, 0.0278
Triglycerides -0.0505* -0.0902, -0.0107 -0.0194 -0.055, 0.0163
Blood sugar
Glucose -0.013 -0.0721, 0.0462 0.0271 -0.0305, 0.0846
Insulin resistance 0.0414* -0.0142, 0.097 0.0101 -0.039, 0.0593
HbA1c -0.0277 -0.0913, 0.0359 -0.0172 -0.0796, 0.0452
Circulatory pressure
Systolic blood pressure -0.0789* -0.119, -0.0385 0.00514 -0.0291, 0.0394
Diastolic blood pressure 0.0336* 0.00886, 0.0584 -0.0143 -0.0417, 0.013
Pulse rate -0.015 -0.0384, 0.00827 -0.0314 -0.0557, -0.00706
Proinflammatory
C-reactive protein -0.0138 -0.0663, 0.0387 -0.0286 -0.0781, 0.021
Fibrinogin -0.0158 -0.0627, 0.031 0.015 -0.0313, 0.0612
Kidney function
Cystatin C -0.0292** -0.0483, -0.0101 -0.0136 -0.0377, 0.0105
Glomerular filtration rate 0.123 0.0858, 0.16 -0.00206 -0.0465, 0.0424
Albumin: Creatinine 0.0434 -0.0159, 0.103 0.0119 -0.0451, 0.069
Adiposity
BMI 0.0705 0.00938, 0.132 -0.0417 -0.108, 0.0241
waist circumference -0.0809* -0.147, -0.0147 0.0306 -0.0359, 0.0971
% body fat -0.0415 -0.0763, -0.0067 -0.00753 -0.0477, 0.0327
The effective sample size for each of the models was 3,407 because of the use of fasting sample weights.
Model 1 includes only the 17 biomarkers shown in the table. Model 2 additionally adjusts for the following
covariables: race/ethnicity (white, Mexican American, black, and other), gender, foreign birthplace,
education (less than high school, high school diploma, more than high school), class of work (white collar
high, blue collar high, white collar low, blue collar low, no work), income, marital status (married or living with
partner), age (as continuous), and age-squared.
doi:10.1371/journal.pmed.1002188.t005
Leukocyte Telomere Length and Biomarkers of Cardiovascular Disease Risk
PLOS Medicine | DOI:10.1371/journal.pmed.1002188 November 29, 2016 17 / 24
The strengths of this study are that we for the first time examine telomere length with bio-
markers that are risk factors for morbidity and mortality in a multi-ethnic nationally represen-
tative sample of the US population. We also examined these associations across a broad age
range of the population, from 25 to 84, based on interest in how LTL acts as a marker of bio-
logical aging across the life course. In addition, we examine this in a general population sample
controlling for a greater number of potentially confounding factors as compared to other stud-
ies. We also are able to examine a wide range of cardiovascular risk biomarkers given the
detailed measurements available in the NHANES data. No studies we are aware of have been
able to examine this many biomarkers in a comparative manner nor to control for white cell
type frequencies. Our findings should be considered generalizable to the US noninstitutional-
ized population from the ages of 25 to 84.
The study has several limitations. Most importantly, our results do not contribute to an
understanding of the directionality of any associations because of the cross-sectional nature of
the data. Causal inference from our findings is not possible. This refers to both the direction of
potential causation between cardiovascular risk markers and LTL as well as the potential con-
founding of the biomarkers themselves. For example, it may be a dietary factor, rather than
adiposity, that is the direct cause of changes in LTL. However, the goal of our study is to deter-
mine whether LTL is largely independent of other cardiovascular disease risk markers, and,
thus, causal inference is not our intention. Randomized trials and quasi-experimental methods
are more suited to the separate and also important question of how LTL may act as a cause or
marker for cardiovascular disease risk. Secondly, although not a limitation per se, our results
must be interpreted specifically with respect to LTL, because telomere length is cell type specific.
Moreover, although we found that controlling for broad measures of cell type reduced magni-
tudes of association, we were not able to examine specific types of T and B cells where different
telomere lengths have been demonstrated [15]. All of our conclusions about which physiological
systems LTL is related to are limited by the commonly used clinical measures of those systems.
In addition, we were not able to perform a mediation analysis for cardiovascular mortality due
to the weak relationship between LTL and relatively short-term (mean 9.5 years) cardiovascular
mortality follow-up available from NHANES [45]. In addition, although we use standard clini-
cal cut-points for our analysis, we do not take into account that these may differ for best differ-
entiating risk in population subgroups. Finally, our baseline data come from 1999–2002 and not
from more recent data collection. Several facts mitigate this potential limitation. First, the actual
telomere length assays were done in 2011, using more recent methodological approaches, and,
thus, the assays themselves were done recently on stored DNA. Secondly, most of the popula-
tion aged 25–84 that were part of the collection of data in 1999–2002 are still alive, so inference
is still about the current US population. We are also not aware of any data suggesting that the
relationship between LTL and cardiovascular biomarkers has changed since 1999–2002.
The results from our study can be compared to other studies that have previously examined
similar factors and LTL. As mentioned in the introduction, the largest prior analysis found
similar findings with respect to adiposity related measures and inflammation [8], with our
study confirming these findings in a larger multi-ethnic US population. The most commonly
examined cardiovascular risk factor with LTL has been BMI, and a recent meta-analysis sum-
marized the results of five prior studies that controlled for covariables in regression analyses,
finding an overall adjusted regression coefficient of -0.008 kBP per BMI unit [46] from 4,183
individuals. Our single study of a larger nationally representative population found a weaker
association of -0.0047 kBP per BMI unit, which may in part be due to our ability to control for
a greater number of potentially confounding factors.
We also found inverse associations with an inflammatory marker (C-reactive protein) in
contrast with prior, more limited studies. A prior study in a sample of individuals over the age
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Fig 5. Generalized additive mixed models of the association between biomarkers and LTL (in kb
pairs), ages 20–84, NHANES 1999–2002.
doi:10.1371/journal.pmed.1002188.g005
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of 70 did not find an association with C-reactive protein [47]. The differences in our findings
are, however, consistent with genetic instrumental variables findings showing SNPs for C-
reactive protein are associated with LTL [48]. In comparison to prior work [49], we did not
find associations with measures of blood sugar and systolic blood pressure. Our findings for
systolic blood pressure were also different from findings in a Costa Rican population, in which
higher systolic blood pressure was found to be associated with longer telomere length [9].
Our findings can also be compared to those from an environmental wide association study
between LTL and 461 environmental, behavioral, and clinical variables using the same
NHANES data [50]. This study found 22 out of 461 associations, with false discovery rate of
<5%. Comparable findings similar to those in our study include C-reactive protein, trunk fat
(a measure of adiposity), and pulse rate. Our approach of targeting 17 cardiovascular disease
biomarkers with a hypothesis-driven approach gave us more power to detect associations than
in this prior study, which is the most likely explanation for our findings with additional adi-
posity measures, diastolic blood pressure, and HDL cholesterol. In addition, we controlled for
white blood cell type, examined clinical cut-points of biomarkers, and examined nonlinearity
of associations. As shown in our study, we missed the association between LTL and diastolic
blood pressure when using a continuous measure rather than a clinical cut-point. Our findings
were also similar to this prior study in finding little evidence for effect measure modification
by gender and race/ethnicity.
Our study has implications for understanding how LTL may be relevant as a biomarker of
aging. LTL is most associated with adiposity, immune function, diastolic blood pressure, pulse,
and HDL cholesterol. This gives suggestions to the underlying role for LTL as a marker for cor-
onary heart disease risk through oxidative stress-related pathways resulting in immune cell
turnover and subsequent shorter LTL [47], consistent with the links between inflammation,
adiposity, and oxidative stress [51]. Furthermore, our evidence is consistent with LTL as
related to different aspects of biological dysregulation. Given the range of biomarkers mea-
sured in this large sample, it enabled us to test whether LTL truly reflects cumulative dysregu-
lation across systems. The findings suggest that telomere length is indeed related to
biomarkers of multiple regulatory systems that indicate risk for cardiovascular disease and
possibly other diseases as well. There were relations across adiposity, inflammatory markers,
and circulatory pressure. Multiple dysregulation across systems has been measured as a sum-
mary variable of unhealthy values across systems called allostatic load. Here, it appears LTL
may serve as a cellular-based indicator of systemic allostatic load.
However, there were not relations across all systems; specifically, there were weaker or non-
existent relationships with blood sugar. With respect to this finding, prior studies have found
differences in LTL between those with and without diabetes [52], which may be a more
extreme comparison than looking at whether there is an association in a representative sample
of the population. We do find consistent results in our basic model that does not control for
demographic confounding variables, but this association is eliminated after controlling for a
large set of potential confounding factors, which may also explain differences in results. A
meta-analysis identifying an association between LTL and diabetes did not examine what
potential confounding factors were controlled for [53]. In addition, studies showing greater
mortality for those with shorter telomere length within diabetic populations [54] are more
informative about the role of telomere length in the progression of disease rather than in the
general population. With respect to kidney function, many prior studies reporting an associa-
tion with LTL were in clinical samples, not in the general population [55]. Other work showing
an association with kidney function and aging has been using telomere length from kidney tis-
sue, not leukocytes [56]. Thus, although blood sugar and kidney function clearly contribute to
cardiovascular risk, their dysregulation in the general population does not seem to be captured
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by LTL, with the exception of some of our models showing a weak association with cystatin C.
Again, however, it is important to consider that we used only established clinical risk factors
for cardiovascular disease to capture the association of LTL with different physiological sys-
tems. Work taking a metabolomics approach has identified more specific biological compo-
nents associated with LTL [57].
Future studies should continue to investigate the relationship between known cardiovascu-
lar biomarkers and LTL in more dynamic ways, including changes over time in both biomark-
ers and LTL. Most critically, in order to understand the clinical relevance for cardiovascular
disease, longer duration follow-up studies that allow for mediation analysis with clinical end-
points must be designed to identify where there may be value added for the assay of LTL
beyond traditional cardiovascular biomarkers. Finally, more complete measures of proinflam-
matory response should be examined to more specifically investigate how LTL is a marker of
this system, ideally on cells that have been sorted by type [15].
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